News >

Expert Highlights Assay to Determine Patients With Lung, Gastrointestinal Cancers to Receive Pembrolizumab

Shannon Connelly
Published: Friday, Aug 10, 2018

Lawrence M. Weiss, MD

Lawrence M. Weiss, MD
The PD-L1 immunohistochemistry (IHC) 22C3 pharmDx can be an aid in identifying patients with non–small cell lung cancer (NSCLC) and gastrointestinal cancers who are eligible for pembrolizumab (Keytruda) monotherapy, according to Lawrence M. Weiss, MD.

This assay is approved by the FDA as a companion diagnostic for pembrolizumab in NSCLC and gastric/gastroesophageal junction (GEJ) adenocarcinoma.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Oncology Consultations®: Discussing the Nurse's Role in Treating and Managing Advanced Pancreatic AdenocarcinomaSep 28, 20191.5
Publication Bottom Border
Border Publication